By
Drug Target Review2023-11-28T16:00:19
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-19T08:26:00Z
2026-06-17T12:40:00Z
2026-06-17T09:14:00Z
2026-06-15T11:00:00Z
Sponsored by Miltenyi Biotec
2023-03-20T13:41:33
Sponsored by Bio-Techne
2026-06-15T11:00:00
Sponsored by Miltenyi Biotec
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2026-03-11T14:00:00
Sponsored by Merck
Site powered by Webvision Cloud